Romain Rivoirard

Saint-etienne-de-valoux, FR 
Saint-etienne-de-valoux, FR 

Overview

Romain Rivoirard practices practicing medicine in Saint-etienne-de-valoux, France.

His clinical expertise encompasses Oligodendroglioma, Glioma, Astrocytoma, and Gliomatosis Cerebri.

He is actively involved in clinical research, co-authoring 58 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

Saint-etienne-de-valoux, France
Other Locations
Saint-priest-la-vetre, France
108 Bis, Avenue Albert Raimond, BP60008, 42271 Saint Priest En Jarez Cedex, EMR3738, Oullins, 69921, France
St. Priest En Jarez Cedex, France
St Priest En Jarez Cedex, Sete, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: Intensified Protocol, Stupp Protocol
Study Phase: Phase 3
Influence of PARAmedical Interventions on Patient ACTivation in the Cancer Care Pathway
Influence of PARAmedical Interventions on Patient ACTivation in the Cancer Care Pathway
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Genetic
Study Phase: Not Applicable
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Enrollment Status: Completed
Publish Date: April 04, 2022
Prospective Multicentric Evaluation of a Bladder Preservation Strategy Using a Combination of Neoadjuvant Chemotherapy and Optimal Bladder Transurethral Resection in Patients With a Urothelial Carcinoma
Prospective Multicentric Evaluation of a Bladder Preservation Strategy Using a Combination of Neoadjuvant Chemotherapy and Optimal Bladder Transurethral Resection in Patients With a Urothelial Carcinoma
Enrollment Status: Terminated
Publish Date: December 30, 2021
Intervention Type: Drug
Study Drug: Optimal TURB
Study Phase: Phase 2
CHEMOIMMUNE - A Phase II Study Evaluating an Anti-PD1 Monoclonal Antibody (Pembrolizumab) in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide
CHEMOIMMUNE - A Phase II Study Evaluating an Anti-PD1 Monoclonal Antibody (Pembrolizumab) in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide
Enrollment Status: Completed
Publish Date: September 10, 2021
Intervention Type: Drug
Study Phase: Phase 2
Description the Geriatric Intervention Contribution on Quality of Life of Elderly Patients With Metastatic Neoplasia : Prospective Descriptive Non-comparative Cohort ( QUALI Cohort)
Description the Geriatric Intervention Contribution on Quality of Life of Elderly Patients With Metastatic Neoplasia : Prospective Descriptive Non-comparative Cohort ( QUALI Cohort)
Enrollment Status: Terminated
Publish Date: July 07, 2020
Intervention Type: Other
View 6 Less Clinical Trials

58 Total Publications

Correction: Influence of capping chemotherapy prescriptions on efficacy and tolerability in medium and high-risk early-stage breast cancer.
Correction: Influence of capping chemotherapy prescriptions on efficacy and tolerability in medium and high-risk early-stage breast cancer.
Journal: Scientific reports
Published: December 24, 2025

Frequently Asked Questions about Romain Rivoirard

Is Romain Rivoirard a top-rated expert for Oligodendroglioma?

MediFind is an objective health platform that identifies experts based on real-world data. Romain Rivoirard is classified as an Experienced expert for Oligodendroglioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Romain Rivoirard participate in research or clinical trials?

Yes. Romain Rivoirard has published 58 articles and abstracts on conditions like Oligodendroglioma. You can view a list of Romain Rivoirard's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rivoirard's expertise for a condition
ConditionClose
        View All 20 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile